Literature DB >> 18628425

Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study.

Bolormaa Dondog1, Gary M Clifford, Salvatore Vaccarella, Tim Waterboer, Davaajav Unurjargal, Damdin Avirmed, Sharkhuu Enkhtuya, Friedrich Kommoss, Nicolas Wentzensen, Peter J F Snijders, Chris J L M Meijer, Silvia Franceschi, Michael Pawlita.   

Abstract

Data on human papillomavirus (HPV) and cervical cancer burden in Central Asia are scarce. To investigate HPV infection in Ulaanbaatar, the capital of Mongolia, we obtained cervical cell specimens from a population of 969 women ages 15 to 59 years. DNA of 44 HPV types was detected using a GP5+/6+ PCR-based assay. Seropositivity for L1 proteins of HPV 16, 18, 31, 33, 45, 52, and 58 was assessed using multiplex HPV serology. Cytologic abnormalities were detected in 127 women (13.1%), among whom 6 cervical intraepithelial neoplasia grade 3 and 2 invasive cervical cancers were diagnosed. Overall HPV DNA prevalence was 35.0%, being highest (48.5%) in women ages <25 years. High-risk types were detected in 24.5% of women. HPV DNA prevalence declined with age but remained >25% in all age groups. HPV seroprevalence was also very high (38.0%) and increased steadily from 33.2% to 48.9% in women ages <25 and 50 to 59 years, respectively. However, the proportion of women positive for both HPV markers of any individual HPV type was low. HPV16 was the most frequently detected type by PCR (6.1%), serology (23.0%), or both (2.1%). Lifetime number of sexual partners and induced abortions were shown to be directly associated with HPV DNA and/or seroprevalence. HPV prevalence in Ulaanbaatar was higher than that detected by similar HPV testing protocols in other populations in Asia or elsewhere and would suggest an important, yet unquantified, cervical cancer burden. Improving cervical cancer prevention, through screening and HPV vaccination, is an important public health issue for Mongolia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628425     DOI: 10.1158/1055-9965.EPI-07-2796

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.

Authors:  Delynn M Moss; Jeffrey W Priest; Alexis Boyd; Tiffany Weinkopff; Zuzana Kucerova; Michael J Beach; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 2.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

3.  Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

4.  Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.

Authors:  Arezoo Aghakhani; Setareh Mamishi; Shahram Sabeti; Farahnaz Bidari-Zerehpoosh; Mohammad Banifazl; Anahita Bavand; Amitis Ramezani
Journal:  Med Microbiol Immunol       Date:  2016-11-17       Impact factor: 3.402

5.  Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.

Authors:  Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson
Journal:  Int J Cancer       Date:  2012-01-27       Impact factor: 7.396

6.  Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.

Authors:  Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2016-03       Impact factor: 2.830

7.  Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study.

Authors:  Shohreh F Farzan; Tim Waterboer; Jiang Gui; Heather H Nelson; Zhongze Li; Kristina M Michael; Ann E Perry; Steven K Spencer; Eugene Demidenko; Adele C Green; Michael Pawlita; Margaret R Karagas
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

8.  Determinants of seropositivity among HPV-16/18 DNA positive young women.

Authors:  Carolina Porras; Christina Bennett; Mahboobeh Safaeian; Sarah Coseo; Ana Cecilia Rodríguez; Paula González; Martha Hutchinson; Silvia Jiménez; Mark E Sherman; Sholom Wacholder; Diane Solomon; Leen-Jan van Doorn; Catherine Bougelet; Wim Quint; Mark Schiffman; Rolando Herrero; Allan Hildesheim
Journal:  BMC Infect Dis       Date:  2010-08-11       Impact factor: 3.090

9.  Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay.

Authors:  Markus Schmitt; Bolormaa Dondog; Tim Waterboer; Michael Pawlita; Massimo Tommasino; Tarik Gheit
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

10.  Differences in the risk of cervical cancer and human papillomavirus infection by education level.

Authors:  S Franceschi; M Plummer; G Clifford; S de Sanjose; X Bosch; R Herrero; N Muñoz; S Vaccarella
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.